Aliases & Classifications for Macular Holes

MalaCards integrated aliases for Macular Holes:

Name: Macular Holes 12 54 15 17 71
Macular Hole 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:7633
MeSH 43 D012167
NCIt 49 C34795
UMLS 71 C0024441

Summaries for Macular Holes

MalaCards based summary : Macular Holes, also known as macular hole, is related to microvascular complications of diabetes 5 and retinal detachment. An important gene associated with Macular Holes is TGFB2 (Transforming Growth Factor Beta 2), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Rheumatoid arthritis. The drugs Ranibizumab and Verteporfin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotype is immune system.

Wikipedia : 74 A macular hole is a small break in the macula, located in the center of the eye's light-sensitive tissue... more...

Related Diseases for Macular Holes

Diseases related to Macular Holes via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 5 31.6 VEGFA TGFB2 SERPINF1 ANGPT2
2 retinal detachment 31.6 VEGFA SERPINF1 RS1 CCL2
3 scotoma 31.4 VEGFA RPE65 KCNMA1
4 uveitis 30.8 TGFB2 SERPINF1 CCL2
5 macular retinal edema 30.8 VEGFA SERPINF1 KCNMA1 CCL2 ANGPT2
6 retinal vein occlusion 30.6 VEGFA SERPINF1 CCL2 ANGPT2
7 diabetic macular edema 30.5 VEGFA SERPINF1 CCL2
8 kuhnt-junius degeneration 30.5 VEGFA SERPINF1 FAM187A ANGPT2
9 microvascular complications of diabetes 1 30.5 VEGFA TGFB2 SERPINF1 CCL2 ANGPT2
10 intraocular pressure quantitative trait locus 30.5 VEGFA TGFB2 SERPINF1
11 neovascular glaucoma 30.2 VEGFA TGFB2 RS1
12 melanoma, uveal 30.0 VEGFA TGFB2 MIR93 MIR9-1
13 preretinal fibrosis 30.0 VEGFA TGFB2 FN1 ANGPT2
14 retinal vascular disease 29.9 VEGFA SERPINF1 FN1 CCL2 ANGPT2
15 vitreous detachment 29.8 VEGFA OPTC LHFPL5 KCNMA1 FN1 FAM187A
16 stargardt disease 29.8 RS1 RPE65 KCNMA1
17 vitreoretinopathy, neovascular inflammatory 29.8 VEGFA TGFB2 RPE65 FN1 CCL2 ADM
18 retinal vascular occlusion 29.8 VEGFA KCNMA1 CCL2
19 exudative vitreoretinopathy 1 29.5 VEGFA SERPINF1 FN1 CCL2 ANGPT2
20 eye disease 28.8 VEGFA TGFB2 SERPINF1 RS1 RPE65 MIR9-1
21 macular degeneration, age-related, 1 28.7 VEGFA SERPINF1 RS1 RPE65 OPTC KCNMA1
22 retinal perforation 28.3 VEGFA RS1 RPE65 OPTC LHFPL5 FN1
23 retinal disease 11.6
24 myopia 11.0
25 cataract 10.8
26 retinoschisis 1, x-linked, juvenile 10.7
27 refractive error 10.7
28 hydrops, lactic acidosis, and sideroblastic anemia 10.6
29 vitreoretinopathy 10.6
30 neuroretinitis 10.6
31 microvascular complications of diabetes 2 10.6
32 retinitis 10.5
33 endophthalmitis 10.5
34 telangiectasis 10.5
35 retinitis pigmentosa 10.5
36 alport syndrome 10.4
37 47,xyy 10.4
38 lipodermatosclerosis 10.4 VEGFA ANGPT2
39 coats disease 10.4
40 central retinal vein occlusion 10.4
41 chorioretinitis 10.4
42 coloboma of macula 10.3
43 vitelliform macular dystrophy 10.3
44 epithelioid cell melanoma 10.3 MIR93 MIR9-1 MIR374A
45 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
46 yemenite deaf-blind hypopigmentation syndrome 10.3
47 pars planitis 10.3
48 degenerative myopia 10.3
49 neuropathy 10.3
50 chorioretinal scar 10.3 VEGFA KCNMA1

Graphical network of the top 20 diseases related to Macular Holes:



Diseases related to Macular Holes

Symptoms & Phenotypes for Macular Holes

MGI Mouse Phenotypes related to Macular Holes:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.36 ADM ALOX5AP ANGPT2 CCL2 FN1 MIF

Drugs & Therapeutics for Macular Holes

Drugs for Macular Holes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4 347396-82-1 459903
2
Verteporfin Approved, Investigational Phase 4 129497-78-5
3 Angiogenesis Inhibitors Phase 4
4 Dermatologic Agents Phase 4
5 Photosensitizing Agents Phase 4
6
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
7
Dinoprostone Approved Phase 3 363-24-6 5280360
8
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
9
Nepafenac Approved, Investigational Phase 3 78281-72-8 151075
10
Indomethacin Approved, Investigational Phase 3 53-86-1 3715
11
Bromfenac Approved Phase 3 91714-94-2 60726
12
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
13
Fibrinolysin Investigational Phase 3 9004-09-5
14 Fibrinolytic Agents Phase 3
15 Pharmaceutical Solutions Phase 3
16 Ophthalmic Solutions Phase 3
17 Plasminogen Phase 3
18 Tocolytic Agents Phase 3
19 Lubricant Eye Drops Phase 3
20 Anti-Inflammatory Agents, Non-Steroidal Phase 3
21 Analgesics, Non-Narcotic Phase 3
22 Cyclooxygenase Inhibitors Phase 3
23 Antirheumatic Agents Phase 3
24 Analgesics Phase 3
25
Bevacizumab Approved, Investigational Phase 2 216974-75-3
26
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
27 retinol Phase 1, Phase 2
28 Retinol palmitate Phase 1, Phase 2
29 Dexamethasone 21-phosphate Phase 1
30
tannic acid Approved 1401-55-4
31
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
32
Dipivefrin Approved 52365-63-6 3105
33
Triamcinolone Approved, Vet_approved 124-94-7 31307
34
Timolol Approved 26839-75-8 33624 5478
35
Dorzolamide Approved 120279-96-1 3154 5284549
36
Temazepam Approved, Investigational 846-50-4 5391
37 Orange Approved
38
Povidone Approved 9003-39-8
39
Iodine Approved, Investigational 7553-56-2 807
40
Povidone-iodine Approved 25655-41-8
41
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
42
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
43
Diminazene Experimental 536-71-0
44 Xenon Experimental 7440-63-3
45 Antiparasitic Agents
46 Antiprotozoal Agents
47 Anti-Infective Agents
48 Triamcinolone hexacetonide
49 triamcinolone acetonide
50 Triamcinolone diacetate

Interventional clinical trials:

(show top 50) (show all 132)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-masked, Multicenter, Controlled Study of Effects of Internal Membrane Peeling Surgery in Patients With Idiopathic Macular Hole Measured by Optical Coherence Tomography. Unknown status NCT02905409 Phase 4
2 A Randomized, Comparative, Prospective Study of Anatomical Outcomes With Different Internal Limiting Membrane Peeling Area in Surgery for Idiopathic Macular Hole Completed NCT02930369 Phase 4
3 Impact of Different Fluidic Parameters on Development of Cystoid Macular Edema Following Phacoemulsification Completed NCT01385852 Phase 4
4 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
5 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
6 A Randomized Study Comparing Brilliant Blue and Indocyanine Green as Intravitreal Dye in Macular Pucker and Macular Hole Unknown status NCT01083004 Phase 3
7 Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery Unknown status NCT01820520 Phase 3 brilliant blue G
8 Fingerprick Fresh Blood for Treatment of Chronic Corneal Ulcers, Persistent Epithelial Defects and Dry Eyes Unknown status NCT02153515 Phase 3
9 A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole Completed NCT01429441 Phase 3 Ocriplasmin
10 A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. Completed NCT00798317 Phase 3 Ocriplasmin 125µg;Placebo
11 A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection Completed NCT01889251 Phase 3 Ocriplasmin;Sham injection
12 A Descriptive Study to Evaluate the Effectiveness of the Dye Compound of the Combination of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Completed NCT01627977 Phase 3
13 Vitreous pge2 Level Changes After Topical Administration of Diclofenac 0.1%, Nepafenac 0.3%, Indomethacin 0.5% and Bromfenac 0.09% in Vitrectomy Patients Completed NCT03597867 Phase 3 Dicloftil;Nevanac;Indom;Yellox
14 Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction Recruiting NCT03647267 Phase 3
15 Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease Unknown status NCT02067013 Phase 2 Ranibizumab
16 Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling Unknown status NCT00556244 Phase 1, Phase 2
17 Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin Unknown status NCT00996684 Phase 2 Microplasmin;Placebo control
18 A Dose-escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy Completed NCT00123279 Phase 2 Microplasmin
19 REVOLUTIONARY: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by Ultra Widefield angIOgraphy in combiNAtion With Ranibizumab Study Phase II Completed NCT01247220 Phase 2 Ranibizumab
20 Single-Arm Study Assessing the Effects of Pneumatic Vitreolysis on Macular Hole Recruiting NCT03677869 Phase 2
21 A Prospective, Multi-Center, Single-Dose, Phase 1 Clinical Trial Designed to Evaluate the Pharmacokinetics of Dexamethasone Phosphate Ophthalmic Solution Delivered Via the EyeGate® II Drug Delivery System in Patients Undergoing Vitrectomy for Macular Hole Repair or Epiretinal Membrane Peeling Completed NCT02644694 Phase 1 Dexamethasone Phosphate Ophthalmic Solution
22 The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes Unknown status NCT02081170
23 Surgical Inverted ILM Repositioning as Autologous Dressing for Idiopathic Full Thickness Macular Holes Treatment Unknown status NCT01228188
24 Macular Hole Surgery With and Without Internal Limiting Membrane Peeling:A Systematic Review and Meta-analysis Unknown status NCT01687829
25 Early Vitrectomy for Impending Macular Hole. Multicenter Clinical Trial Unknown status NCT01121965
26 Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy Unknown status NCT01969929
27 Early Vitrectomy for Macular Tractional Maculopathy. Multicenter Clinical Trial Unknown status NCT01121978
28 Intravitreous CytokinE Level in pAtient With retiNal Detachment Unknown status NCT03318588
29 Evaluation Use Optical Coherence Tomography - Rescan During Dissection of Macular Membranes : Pre and Post Operative Aspects Unknown status NCT02748421
30 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel. Unknown status NCT00892619
31 Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients Unknown status NCT02290795
32 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery: Randomised Clinical Trial of Safety Unknown status NCT01959568
33 Virtual Vitreoretinal Surgery: Construction of a Training Program and Analysis of Significant Factors for Operating Performance Unknown status NCT02559661
34 Outcome of Surgery for Idiopathic Macular Holes Completed NCT02895594
35 Preoperative Progression of Macular Holes Using Optical Coherence Tomography Completed NCT02203929
36 Membranepeeling With Brillant Blue Versus Membranepeeling With Indocyanine Green for Patients With Idiopathic Macular Holes. Completed NCT00757471
37 Long-term Outcome of Idiopathic Macular Hole Surgery Completed NCT00941291
38 A Randomized Clinical Trial of Face-down Protocol Versus Non-face-down Protocol After Surgery for Macular Holes. Completed NCT01974310
39 Fundus Autofluorescence Images in Gas-filled Eyes Immediately After Macular Hole Surgery Completed NCT02628262
40 Study of the Anatomic and Visual Outcomes in Patients With Initially Closed Macular Holes After Vitreoretinal Surgery Completed NCT01229657
41 The Application of M-charts and Microperimetry for the Assessment of Visual Function in Patients After Vitrectomy Due to the Full Thickness Macular Hole. Completed NCT03701542
42 Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery Completed NCT01381965
43 Correlation Between Visual Acuity and Recovery of Foveal Cone Microstructures After Macular Hole Surgery Completed NCT01306487
44 Transposition of Internal Limiting Membrane in the Treatment of Macular Holes. A Descriptive Pilot Study Completed NCT02946372
45 Air Tamponade in Macular Holes < 400 μm Completed NCT02028481
46 Asymmetric Elongation of Foveal Tissue After Macular Hole Surgery and Its Impact on Metamorphopsia Completed NCT01471912
47 Pneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole Completed NCT00485199
48 A Randomized, Open Label, Single Center Study Comparing the Efficacy of Macular Buckle Versus Vitrectomy on Full-thickness Macular Hole and Concurrent Macular Detachment in Eyes With Highly Myopia Completed NCT03433547
49 Comparison of Vitrectomy Without Internal Limiting Membrane Peeling Versus Inverted ILM Flap Technique for Macular Hole Retinal Detachment in Highly Myopic Eyes Completed NCT04011007
50 Incidence and Factors Related to Macular Hole Reopening Completed NCT00927628

Search NIH Clinical Center for Macular Holes

Genetic Tests for Macular Holes

Anatomical Context for Macular Holes

MalaCards organs/tissues related to Macular Holes:

40
Eye, Retina, Endothelial, Breast, Testes, Whole Blood, Cortex

Publications for Macular Holes

Articles related to Macular Holes:

(show top 50) (show all 4253)
# Title Authors PMID Year
1
Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease. 54 61
20072643 2009
2
Differential expression of vitreous proteins in proliferative diabetic retinopathy. 54 61
16531280 2006
3
Angiopoietin concentrations in diabetic retinopathy. 54 61
15774928 2005
4
Elevated adrenomedullin in the vitreous of patients with diabetic retinopathy. 54 61
12566874 2003
5
Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. 54 61
12208245 2002
6
Macrophage migration inhibitory factor in ocular fluids of patients with uveitis. 54 61
11673308 2001
7
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. 54 61
11264138 2001
8
Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy. 54 61
10837392 2000
9
Elevated adrenomedullin in the vitreous of patients with proliferative vitreoretinopathy. 54 61
10612519 1999
10
Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy. 54 61
10612518 1999
11
Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery. 54 61
9544645 1998
12
Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2. 54 61
9497468 1997
13
[Surgical management of complete macular foramina]. 54 61
9081519 1996
14
Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade. 54 61
8956640 1996
15
Closure of persistent macular holes with human recombinant transforming growth factor-beta 2. 54 61
8804755 1996
16
Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes. 54 61
9098285 1995
17
Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. 54 61
7785710 1995
18
Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. 54 61
7825689 1995
19
Idiopathic macular hole: a clinical review and current concepts in the diagnosis and management. 54 61
7852702 1994
20
Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. 54 61
8035983 1994
21
Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2. 54 61
8129001 1994
22
Full-thickness macular holes treated with vitrectomy and tissue glue. 54 61
7642336 1994
23
Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study. 54 61
8259275 1993
24
The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. 54 61
8510899 1993
25
Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study. 54 61
8115729 1993
26
Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study. 54 61
1495798 1992
27
NO FACE-DOWN POSITIONING SURGERY FOR THE REPAIR OF CHRONIC IDIOPATHIC MACULAR HOLES. 61
31972798 2020
28
SURGICAL MANAGEMENT OF TRAUMATIC MACULAR HOLE: Optical Coherence Tomography Features and Outcomes. 61
31972799 2020
29
Outcome of autologous platelet concentrate and gas tamponade compared to heavy silicone oil tamponade in persistent macular hole surgery. 61
32019342 2020
30
MACULAR DEHISCENCE-ASSOCIATED EPIRETINAL PROLIFERATION IN EYES WITH FULL-THICKNESS MACULAR HOLE. 61
31972797 2020
31
Idiopathic Macular Hole Preferred Practice Pattern®. 61
31757499 2020
32
Etiologies, Characteristics, and Management of Pediatric Macular Hole. 61
31560879 2020
33
Central mfERG amplitude ratio as a predictor for visual outcome of macular hole surgery. 61
31482394 2020
34
Comparison of various surgical techniques for optic disc pit maculopathy: vitrectomy with internal limiting membrane (ILM) peeling alone versus inverted ILM flap 'plug' versus autologous scleral 'plug'. 61
32029434 2020
35
Long-term results and risk factors influencing outcome of gas tamponade for myopic foveoschisis with foveal detachment. 61
31406352 2020
36
The effectiveness and safety of posterior scleral reinforcement with vitrectomy for myopic foveoschisis treatment: a systematic review and meta-analysis. 61
31823060 2020
37
ANATOMICAL AND VISUAL OUTCOMES OF INVERTED INTERNAL LIMITING MEMBRANE FLAP TECHNIQUE VERSUS INTERNAL LIMITING MEMBRANE PEELING IN MYOPIC MACULAR HOLE WITHOUT RETINAL DETACHMENT: A Preliminary Retrospective Study. 61
31972792 2020
38
Vascularization and Reperfusion of Autologous Retinal Transplant for Giant Macular Holes. 61
31944234 2020
39
Combining cataract surgery with 25-gauge high-speed pars plana vitrectomy: A prospective study. 61
31973558 2020
40
Development and Validation of Deep Learning Models for Screening Multiple Abnormal Findings in Retinal Fundus Images. 61
31281057 2020
41
Near full thickness macular hole with an intact overlying internal limiting membrane following resolution of fulminant acquired toxoplasma retinitis -A unique finding. 61
31856540 2020
42
Correction: Lamellar hole-associated epiretinal membrane is a common featureof macular holes in retinitis pigmentosa. 61
31942028 2020
43
Commentary: Considerations regarding area of internal limiting membrane peeling during macular hole surgery. 61
31856497 2020
44
Pediatric idiopathic macular hole - A case report and review of literature. 61
31856539 2020
45
Combined brilliant blue G and xenon light induced outer retinal layer damage following macular hole surgery. 61
31856542 2020
46
INTERNAL LIMITING MEMBRANE PEELING AND AIR TAMPONADE FOR STAGE III AND STAGE IV IDIOPATHIC MACULAR HOLE. 61
30312258 2020
47
Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole. 61
31934816 2020
48
Tailored internal limiting membrane flap technique for primary macular hole. 61
31900649 2020
49
How Big is the Hole? Measuring Intra- and Inter-Individual Agreement in Macular Hole Size Measurements. 61
31880476 2020
50
HIGH-POWERED BLUE-LIGHT LASER-INDUCED MACULOPATHY IN AN ADOLESCENT: MULTI-MODAL IMAGING, EVOLUTION, AND MANAGEMENT. 61
31958106 2020

Variations for Macular Holes

Expression for Macular Holes

Search GEO for disease gene expression data for Macular Holes.

Pathways for Macular Holes

Pathways related to Macular Holes according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.55 VEGFA FN1 CCL2
2 11.4 VEGFA TGFB2 CCL2
3 11.28 TGFB2 CCL2 ANGPT2
4 10.92 VEGFA TGFB2 FN1 CCL2
5 10.82 VEGFA TGFB2 FN1
6 10.65 VEGFA CCL2

GO Terms for Macular Holes

Cellular components related to Macular Holes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFA TGFB2 SERPINF1 RS1 PTGDS OPTC
2 extracellular space GO:0005615 9.4 VEGFA TGFB2 SERPINF1 RS1 PTGDS MIR93
3 platelet alpha granule lumen GO:0031093 9.33 VEGFA TGFB2 FN1

Biological processes related to Macular Holes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.58 VEGFA TGFB2 SERPINF1
2 negative regulation of gene expression GO:0010629 9.56 VEGFA TGFB2 SERPINF1 MIF
3 prostaglandin biosynthetic process GO:0001516 9.37 PTGDS MIF
4 angiogenesis GO:0001525 9.35 VEGFA TGFB2 FN1 CCL2 ANGPT2
5 response to wounding GO:0009611 9.33 TGFB2 FN1 ADM
6 neural retina development GO:0003407 9.32 TGFB2 RPE65
7 response to hypoxia GO:0001666 9.02 VEGFA TGFB2 KCNMA1 ANGPT2 ADM

Molecular functions related to Macular Holes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 VEGFA TGFB2 MIF CCL2
2 signaling receptor binding GO:0005102 9.1 TGFB2 MIF FN1 CCL2 ANGPT2 ADM

Sources for Macular Holes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....